Table 1 Patient demographics and clinical data. We analysed the demographic and clinical data of 22 patients with a histologically confirmed IPF diagnosis. 11 of the patients underwent VATS and had mild-to-moderate fibrotic changes in the lung. Another 11 IPF patients underwent lung transplantation because of severe or end-stage fibrosis. There was no significant difference between the patient groups’ age, smoking status and body mass index (BMI). The lung function parameters Forced Expiratory Volume in 1 s (FEV1), Forced Vital Capacity (FVC), Total Lung Capacity (TLC) and Transfer factor for carbon monoxide in the lung (TLCO) were significantly higher in the patient group with mild-to-moderate fibrotic changes compared to those with severe or end-stage fibrosis (p < 0.01 using Students unequal variance t-test)
From: Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis
Patients with mild-to-moderate fibrosis (VATS biopsy patients) | Patients with severe or end-stage fibrosis (Lung transplant patients) | p-value (Students t-test) | |
|---|---|---|---|
Demographic and clinical data | |||
N | 11 | 11 | - |
Sex | 4 males, 7 females | 9 males, 2 females | - |
Median age (range) | 66 (39–76) | 58 (44–61) | 0.126 |
Smoking in history (percent) | 7 (63 %) | 7 (63 %) | 0.482 |
Pack years (mean ± SEM) | 28.37 ± 11.97 | 21.93 ± 6.61 | 0.784 |
BMI (mean ± SEM) | 28.87 ± 1.37 | 27.67 ± 1.87 | 0.636 |
Lung function | |||
FEV1 (mean ± SEM) | 2.51 ± 0.19 | 1.59 ± 0.20 | 0.0009 |
FVC (mean ± SEM) | 3.21 ± 0.32 | 1.92 ± 0.23 | 0.0006 |
TLC (mean ± SEM) | 4.77 ± 0.54 | 3.04 ± 0.34 | 0.0014 |
TLCO (mean ± SEM) | 3.69 ± 0.36 | 2.09 ± 0.30 | 0.0099 |
Medication (given only after biopsy) | |||
Prednisolone | 6 (54.5 %) | 8 (72.7 %) | - |
Azathioprine | 3 (27.2 %) | 4 (36.3 %) | - |
N-acetylcysteine | 4 (36.3 %) | 2 (18.1 %) | - |